Impact of substance abuse on polycystic ovarian syndrome

Abstract Polycystic ovary syndrome (PCOS) intersects with substance use through specific biological pathways, as demonstrated by this systematic review of 87 peer-reviewed studies from 2014 to 2024. The analysis reveals three clinically significant mechanisms: chronic alcohol consumption (> 3 drinks/day) elevates serum testosterone through dual pathways—reducing hepatic SHBG production by 40–60% while directly stimulating ovarian theca cell androgen synthesis via oxidative stress. Nicotine exposure differentially impacts PCOS phenotypes, exacerbating adrenal hyperandrogenism in obese patients through nAChRα7-mediated 17α-hydroxylase upregulation while showing minimal metabolic effects in lean individuals. Cannabis use alters reproductive neuroendocrinology, with weekly consumption correlating to prolonged follicular phases and reduced ovulation rates through CB1 receptor-mediated suppression of LH surge amplitude. These substance-specific interactions compound core PCOS pathophysiology. Alcohol’s hepatic effects amplify existing hyperandrogenemia, nicotine’s adrenal stimulation creates an additional androgen source beyond ovarian dysfunction, and cannabis-induced gonadotropin disruption exacerbates anovulation. Clinically, the findings necessitate routine substance use screening in PCOS management and phenotype-specific interventions—particularly adrenal-focused approaches for nicotine users and GnRH pulse stabilization for cannabis consumers. The review identifies critical research gaps, including dose–response thresholds for substance effects and demographic disparities in study populations. Future investigations should prioritize longitudinal designs to establish temporal relationships and controlled interventions targeting identified mechanisms. These evidence-based insights refine clinical understanding of how specific substances modify PCOS trajectories, moving beyond generalized associations to delineate actionable biological pathways for therapeutic targeting.

Authors

Institutions

Publication Details

Journal
Discover Endocrinology and Metabolism
Published
2025-09-24
DOI
https://doi.org/10.1007/s44417-025-00004-1
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of substance abuse on polycystic ovarian syndrome

Moyinoluwa Comfort Onaolapo, Lydia Oluwatoyin Ajayi, Ayodeji Folorunsho Ajayi, Oyedayo Phillips Akano et al.
Discover Endocrinology and Metabolism
Ovarian function and disorders
article

Impact of substance abuse on polycystic ovarian syndrome

Moyinoluwa Comfort Onaolapo, Lydia Oluwatoyin Ajayi, Ayodeji Folorunsho Ajayi, Oyedayo Phillips Akano, Grace Bosede Akanbi, Aduragbemi Hezekiah Ayodele, Mariam Omotola Alabi, Grace Oluwatomiwa Gbenga
article en

Abstract

Abstract Polycystic ovary syndrome (PCOS) intersects with substance use through specific biological pathways, as demonstrated by this systematic review of 87 peer-reviewed studies from 2014 to 2024. The analysis reveals three clinically significant mechanisms: chronic alcohol consumption (> 3 drinks/day) elevates serum testosterone through dual pathways—reducing hepatic SHBG production by 40–60% while directly stimulating ovarian theca cell androgen synthesis via oxidative stress. Nicotine exposure differentially impacts PCOS phenotypes, exacerbating adrenal hyperandrogenism in obese patients through nAChRα7-mediated 17α-hydroxylase upregulation while showing minimal metabolic effects in lean individuals. Cannabis use alters reproductive neuroendocrinology, with weekly consumption correlating to prolonged follicular phases and reduced ovulation rates through CB1 receptor-mediated suppression of LH surge amplitude. These substance-specific interactions compound core PCOS pathophysiology. Alcohol’s hepatic effects amplify existing hyperandrogenemia, nicotine’s adrenal stimulation creates an additional androgen source beyond ovarian dysfunction, and cannabis-induced gonadotropin disruption exacerbates anovulation. Clinically, the findings necessitate routine substance use screening in PCOS management and phenotype-specific interventions—particularly adrenal-focused approaches for nicotine users and GnRH pulse stabilization for cannabis consumers. The review identifies critical research gaps, including dose–response thresholds for substance effects and demographic disparities in study populations. Future investigations should prioritize longitudinal designs to establish temporal relationships and controlled interventions targeting identified mechanisms. These evidence-based insights refine clinical understanding of how specific substances modify PCOS trajectories, moving beyond generalized associations to delineate actionable biological pathways for therapeutic targeting.

Discover Endocrinology and MetabolismVol. 1(1)
Adeleke University (NG), Ladoke Akintola University of Technology (NG), Olabisi Onabanjo University (NG)
Federal Aviation Administration
Openalex Percentile: Top 66%
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.